Antimicrobial drug developer HOOKIPA Pharma (NASDAQ:HOOK) announced Thursday that Gilead Sciences (NASDAQ:GILD) has agreed to acquire some of its assets for a total consideration of up to $10M. In ...

Gilead paid Hookipa $4 million for a one-time preclinical milestone last month under their original 2018 pact, but the Big Pharma decided to opt out of taking the immunotherapy into the clinic, ...

Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per share; Following the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s ...

Hookipa Biotech AG Joern Aldag, CEO [email protected] or Marine Popoff, Communications Analyst [email protected] or Media enquiries Instinctif Partners Sue Charles/ Ashley Tapp ...

Gilead purchased 15 million shares and holds 19.4% stake in HOOKIPA. Equity investment is to advance the Gilead-partnered HIV program through Phase 1 trial expected to start in 1H of 2024. Don't ...

Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated ...

Gilead Sciences GILD entered into a research collaboration and license agreement with Hookipa Biotech AG. Per the agreement, Gilead will own.

--HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Gilead Sciences has purchased 15 million shares of ...

Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated ...

Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s ...